Building this hour’s briefing
Fetching wire and national feeds…
Business5 outlets · 3 countries
This briefing item
First published 2 hours ago (Oct 2, 2026, 3:13 PM UTC) · latest update Oct 2, 2026, 3:13 PM UTC
Independent
5
Public broadcasters
0
State-backed
0
Stance mix in this cluster
United States · 2
United Kingdom · 2Global · 1Cross-referenced facts
Prism keeps a sentence only when at least two write-ups share the same core details. Adjectives that signal a take are stripped. This is not a verdict — it is the overlapping record.
Headlines in this cluster diverge enough that no sentence repeated cleanly. Shared names and figures are listed below; treat single-source claims as unverified here.
Claims that appeared in only one write-up, each labeled by outlet.
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s.
‘Godzilla’ of weight-loss drugs could provide other important health benefits.
Lilly’s Next-Gen Obesity Drug Helps People Lose Even More Weight in Study.
Sources are ordered left → neutral → right so the spread is visible. Stance is a coarse editorial label for comparison, not a moral score. Timestamps are the time each item entered the feed.
The Guardian
United Kingdom · Independent
theguardian.com/science/2026/sep/29/retatrutide-godzilla-of-weight-loss-drug…
CNBC
United States · Independent
cnbc.com/2026/10/02/lilly-novo-amylin-obesity-drugs.html
Reuters
United Kingdom · Independent · Wire service. Used as a factual baseline when present.
reuters.com/legal/litigation/experimental-lilly-combination-drug-tops-ze…
Scientific American
Global · Independent · Not in Prism’s outlet directory; labels are a conservative default.
scientificamerican.com/article/blockbuster-retatrutide-trial-signals-a-new-high-wat…
The Wall Street Journal
United States · Independent
wsj.com/health/pharma/lillys-next-gen-obesity-drug-helps-people-lose…